Citadel Advisors
BNTX icon

Citadel Advisors’s BioNTech BNTX Stock Holding History

Citadel Advisors’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.2M Buy
452,715
+302,615
+202% +$31.1M 0.01% 1566
2025
Q4 		$14.3M Sell
150,100
-98,300
-40% -$9.9M ﹤0.01% 2765
2025
Q3 		$24.5M Buy
248,400
+77,600
+45% +$8.3M ﹤0.01% 2081
2025
Q2 		$18.2M Sell
170,800
-55,900
-25% -$5.65M ﹤0.01% 2262
2025
Q1 		$20.6M Sell
226,700
-167,900
-43% -$18.8M ﹤0.01% 2001
2024
Q4 		$45M Sell
394,600
-136,200
-26% -$15.5M 0.01% 1368
2024
Q3 		$63M Buy
530,800
+202,100
+61% +$18.6M 0.01% 1020
2024
Q2 		$26.4M Buy
328,700
+163,300
+99% +$14.9M 0.01% 1721
2024
Q1 		$15.3M Buy
165,400
+24,700
+18% +$2.37M ﹤0.01% 2380
2023
Q4 		$14.8M Sell
140,700
-86,000
-38% -$8.67M ﹤0.01% 2355
2023
Q3 		$24.6M Sell
226,700
-82,300
-27% -$9.1M 0.01% 1657
2023
Q2 		$33.4M Sell
309,000
-15,700
-5% -$1.77M 0.01% 1392
2023
Q1 		$40.4M Sell
324,700
-262,600
-45% -$36.1M 0.01% 1260
2022
Q4 		$88.2M Sell
587,300
-34,400
-6% -$5.29M 0.02% 715
2022
Q3 		$83.9M Sell
621,700
-281,900
-31% -$43.1M 0.02% 702
2022
Q2 		$135M Sell
903,600
-240,700
-21% -$36.8M 0.03% 430
2022
Q1 		$195M Sell
1,144,300
-30,500
-3% -$5.13M 0.04% 352
2021
Q4 		$303M Sell
1,174,800
-770,300
-40% -$211M 0.06% 209
2021
Q3 		$531M Buy
1,945,100
+1,177,500
+153% +$374M 0.11% 103
2021
Q2 		$172M Buy
767,600
+120,000
+19% +$22.6M 0.04% 387
2021
Q1 		$70.7M Buy
647,600
+341,300
+111% +$36.2M 0.02% 782
2020
Q4 		$25M Buy
306,300
+203,900
+199% +$20M 0.01% 1574
2020
Q3 		$7.09M Buy
102,400
+90,100
+733% +$6.46M ﹤0.01% 2684
2020
Q2 		$821K Buy
+12,300
New +$614K ﹤0.01% 6195

Other funds holding BNTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GP
GSK plc London $599M AUM

Citadel Advisors's BNTX Position: Q1 2026 in Review

Citadel Advisors increased its BioNTech (BNTX) stake by 40% in Q1 2026, buying an estimated $28.1M and bringing the position to 951,372 shares worth $84.6M. The position accounts for 0.01% of the portfolio, ranked #932.

Citadel Advisors first reported a position in BNTX in Q2 2020 and has held it in 24 quarters since. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • Citadel Advisors held 951,372 shares of BioNTech worth $84.6M as of Q1 2026.
  • Citadel Advisors bought 273,197 BioNTech shares in Q1 2026, an estimated $28.1M.
  • BioNTech made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #932 holding.
  • Citadel Advisors first reported a position in BioNTech in Q2 2020 and has held it in 24 quarters since.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.